Skip to main content

Table 1 Baseline characteristics of the whole study population according to the modified Rankin Scale (mRS) at 3 months (n = 342)

From: Association of admission neutrophil serine proteinases levels with the outcomes of acute ischemic stroke: a prospective cohort study

 

Total

Favorable outcomea

Unfavorable outcome

p value

(N = 342)

(N = 222)

(N = 120)

Demographic characteristics

 Age, y, mean (SD)

64.4 (12.9)

63.6 (12.0)

66.0 (14.3)

0.094

 Female sex (%)

89 (26.0)

57 (64.0)

32 (36.0)

0.944

 BMI, kg/m2, median [IQR]

25.4 [23.5, 27.4]

25.4 [23.3, 27.2]

25.8 [23.7, 27.4]

0.742

Medical history

 Hypertension

229 (67.0)

145 (65.3)

84 (70.0)

0.448

 Diabetes mellitus

122 (35.8)

75 (33.9)

47 (39.2)

0.399

 Hyperlipemia

86 (29.8)

64 (33.5)

22 (22.4)

0.070

 Coronary heart disease

68 (19.9)

39 (17.6)

29 (24.2)

0.188

 Atrial fibrillation

54 (15.8)

28 (12.6)

26 (21.7)

0.042†

 Recurrent stroke

102 (37.1)

63 (35.4)

39 (40.2)

0.502

 Smoking habit

89 (26.0)

64 (28.8)

25 (20.8)

0.121

Stroke characteristics and treatment

 Admission NIHSS score

6.0 [3.0, 12.0]

4.0 [2.0, 7.0]

13.0 [8.0, 17.0]

< 0.001†

 mRS 0–1 prestroke

273 (79.8)

187 (68.5)

86 (31.5)

0.416

 Onset-to-treatment time, h

2.9 [1.5, 4.8]

2.7 [1.4, 4.4]

3.2 [1.8, 6.4]

0.020†

 Intravenous thrombolysis

146 (42.7)

105 (47.3)

41 (34.2)

0.026†

 Endovascular treatment

57 (16.7)

25 (11.3)

32 (26.7)

< 0.001†

Stroke etiology (TOAST), n (%)

 Large artery atherosclerosis

173 (50.6)

109 (49.1)

64 (53.3)

0.526

 Small vessel occlusion

80 (23.4)

62 (27.9)

18 (15.0)

0.010†

 Cardioembolic

26 (7.6)

14 (6.3)

12 (10.0)

0.310

  Other determined

11 (3.2)

5 (2.3)

6 (5.0)

0.292

  Undetermined

52 (15.2)

32 (14.4)

20 (16.7)

0.692

 Posterior circulation stroke

45 (13.2)

28 (12.6)

17 (14.2)

0.812

Clinical and laboratory findings

 Systolic blood pressure, mmHg

150.0 [140.0, 164.8]

150.0 [140.0, 162.8]

150.0 [140.0, 165.2]

0.693

 Diastolic blood pressure, mmHg

85.5 [77.0, 92.0]

85.0 [77.0, 91.0]

89.0 [78.0, 93.5]

0.223

 Serum glucose, mmol/L

7.2 [5.9, 10.1]

6.8 [5.7, 8.8]

8.4 [6.3, 11.8]

0.002†

 HbA1c, %

6.0 [5.5, 7.3]

5.9 [5.5, 7.1]

6.2 [5.5, 7.4]

0.320

 Neutrophils, ×1000/mm3

5.0 [3.9, 6.6]

4.6 [3.7, 5.9]

6.3 [4.5, 8.0]

< 0.001†

 NLR

3.0 [2.0, 5.1]

2.6 [1.8, 4.0]

4.6 [2.7, 7.8]

< 0.001†

 Platelet count, ×1000/mm3

207.0 [171.0, 244.8]

209.0 [174.0, 244.0]

201.0 [168.0, 245.0]

0.378

 HYC, μmol/L

14.5 [11.5, 18.3]

14.6 [11.4, 18.4]

14.5 [11.9, 17.1]

0.621

 TG, mmol/L

1.5 [1.0, 2.4]

1.6 [1.0, 2.6]

1.3 [0.8, 1.8]

0.002†

 TC, mmol/L

4.5 [3.8, 5.4]

4.6 [3.9, 5.4]

4.4 [3.7, 5.0]

0.104

 HDL, mmol/L

1.2 [1.0, 1.4]

1.2 [1.0, 1.4]

1.2 [1.0, 1.4]

0.773

 LDL, mmol/L

2.7 [2.1, 3.4]

2.7 [2.0, 3.5]

2.6 [2.1, 3.2]

0.370

Biological measures

 NE, ng/mL

98.0 [58.6, 278.4]

95.2 [55.9, 214.2]

183.0 [80.2, 444.7]

< 0.001†

 CTSG, ng/mL

212.4 [199.1, 224.1]

213.6 [199.0, 224.7]

210.4 [200.4, 223.4]

0.603

 PR3, ng/mL

388.9 [366.0, 408.9]

386.3 [362.2, 407.1]

392.1 [378.2, 414.4]

< 0.001†

  1. Data for continuous variables are described as mean (SD) (normally distributed variables) or as median [interquartile range] (nonnormally distributed variables), for categorical variables are described as n (%)
  2. BMI body mass index, CTSG cathepsin G, HbA1c hemoglobinA1c, HDL high density lipoprotein, HYC homocysteine, LDL low density lipoprotein, mRS modified Rankin Scale, NE neutrophil elastase, NIHSS NIH Stroke Scale, NLR neutrophil-to-lymphocyte ratio, PR3 proteinase 3, rtPA recombinant tissue plasminogen activator, TC Total cholesterol, TG triglyceride, TOAST Trial of ORG 10172 in Acute Stroke Treatment
  3. †p < 0.05
  4. aThe favorable outcome was defined as an mRS score ≤ 2 or equal to prestroke mRS and the unfavorable outcome was defined as an mRS score > 2
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094